These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Hilli J, Sailas L, Jyrkkiö S, Pyrhönen S, Laine K. Cancer Chemother Pharmacol; 2011 Jun; 67(6):1353-62. PubMed ID: 20798939 [Abstract] [Full Text] [Related]
8. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Messersmith WA, Baker SD, Lassiter L, Sullivan RA, Dinh K, Almuete VI, Wright JJ, Donehower RC, Carducci MA, Armstrong DK. Clin Cancer Res; 2006 Feb 15; 12(4):1270-5. PubMed ID: 16489083 [Abstract] [Full Text] [Related]
11. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. Michael M, Cullinane C, Hatzimihalis A, O'Kane C, Milner A, Booth R, Schlicht S, Clarke SJ, Francis P. Cancer Chemother Pharmacol; 2012 Jan 15; 69(1):125-35. PubMed ID: 21626050 [Abstract] [Full Text] [Related]
14. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. Choi YH, Suh JH, Lee JH, Cho IH, Lee MG. J Pharm Pharmacol; 2010 Aug 15; 62(8):1084-8. PubMed ID: 20663044 [Abstract] [Full Text] [Related]
15. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Clin Pharmacol Ther; 2003 Aug 15; 74(2):170-7. PubMed ID: 12891227 [Abstract] [Full Text] [Related]
16. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS. J Clin Oncol; 2002 Sep 01; 20(17):3683-90. PubMed ID: 12202670 [Abstract] [Full Text] [Related]
18. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Posey JA, Wang H, Hamilton J, Delgrosso A, Zhang R, Freda T, Zamboni WC. Cancer Chemother Pharmacol; 2005 Aug 01; 56(2):182-8. PubMed ID: 15838660 [Abstract] [Full Text] [Related]
19. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5896-901. PubMed ID: 14676112 [Abstract] [Full Text] [Related]
20. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Yan YD, Kim DH, Sung JH, Yong CS, Choi HG. Int J Pharm; 2010 Oct 31; 399(1-2):116-20. PubMed ID: 20727390 [Abstract] [Full Text] [Related] Page: [Next] [New Search]